Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- NHS Tayside
- Target Recruit Count
- 27
- Registration Number
- NCT02733679
- Locations
- 🇬🇧
Ninewells Hospital, Dundee, Angus, United Kingdom
Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Emory University
- Target Recruit Count
- 9
- Registration Number
- NCT02730195
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 18
- Registration Number
- NCT02697617
- Locations
- 🇺🇸
Indiana University Health, Indianapolis, Indiana, United States
Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
- Conditions
- Interventions
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 25
- Registration Number
- NCT02694263
- Locations
- 🇬🇧
University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom
🇬🇧University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom
Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS
- Conditions
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT02689843
- Locations
- 🇮🇷
Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of
Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-22
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Meng Li
- Target Recruit Count
- 20
- Registration Number
- NCT02687425
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02592317
- Locations
- 🇲🇩
Arensia Exploratory Medicine, Chisinau, Moldova, Republic of
🇪🇸Hosp Univ Vall D Hebron, Barcelona, Spain
🇪🇸Hosp. Virgen Del Rocio, Sevilla, Spain
Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI
- Conditions
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Registration Number
- NCT02585765
- Locations
- 🇺🇸
James J. Peters VA Medical Center, Bronx, New York, United States
Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)
- Conditions
- Interventions
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 16
- Registration Number
- NCT02535832
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT02429232
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.